Tropic, a Norwich-based agtech specialising in gene-edited tropical crops, has secured a $105m (£79.2m) Series C funding round.
The company, which uses a proprietary platform to develop improved crops that are resistant to disease with higher yields, is planning the global commercial scale up of its crop portfolios following the sizeable round.
Currently Tropic’s crop portfolio is focused on bananas and rice, which it genetically engineers to meet global agricultural challenges.
Tropic plans to use the Series C capital to expand its large-scale plant production capabilities, strengthen its global supply chains and support commercial partnerships across major export markets.
“This funding is a powerful endorsement of our team’s ability to bring breakthrough products to the hands of growers, exporters and consumers around the world. We are entering a new era, one where gene‑edited crops will significantly enhance food security and sustainability,” said Gilad Gershon, chief executive of Tropic.
“2025 proved that our technology delivers – not in the distant future, but right now. With two banana varieties already on the market and demand outstripping supply, this investment enables us to scale global production and expand into new crops faster than ever before.
“We are excited to be partnering with our new investors as we progress our mission to build a world leading tropical seeds company.”
The funding round was co-led by Forbion, which operates a bioeconomy fund, and Corteva.
“Tropic is an exemplary case of how advanced biotechnology can be applied with precision to challenges in planetary health, starting with banana and rice,” said Forbion general partner Joy Faucher.
“Escalating disease pressure, limited innovation and a lack of cost-effective solutions are driving a growing environmental and supply chain risk in our food systems.”
Additional funding came from Just Climate. IQ Capital, ABN Amro and Invest International, Temasek, Five Seasons Ventures, Sucden Ventures, Genoa Ventures and Polaris Partners.
